Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: Effects on nonmotor symptoms and tolerability

JAMA Neurology

Volumn 72, Issue 1, 2015, Pages 88-95

  Smith, Kara M ^a   Eyal, Eli ^b   Weintraub, Daniel ^a,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b TEVA PHARMACEUTICALS   (Israel)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; ESCITALOPRAM; PAROXETINE; PLACEBO; RASAGILINE; SERTRALINE; ANTIDEPRESSANT AGENT; INDAN DERIVATIVE; NEUROPROTECTIVE AGENT;

ABDOMINAL PAIN; ADULT; AGED; ALCOHOLISM; ANXIETY; APATHY; ARTICLE; COGNITION; CONTROLLED STUDY; DAYTIME SOMNOLENCE; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FACIAL HYPOESTHESIA; FAINTNESS; FATIGUE; HUMAN; HYPESTHESIA; KNEE SURGERY; LARYNGITIS; LARYNX TUMOR; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MYALGIA; NEUROLOGIC DISEASE ASSESSMENT; NONCARDIAC CHEST PAIN; ORAL PARESTHESIA; PARKINSON DISEASE; PARKINSON FATIGUE SCALE; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RECTUM CANCER; SEROTONIN SYNDROME; SLEEP; THORAX PAIN; THYROID TUMOR; UNIFIED PARKINSON DISEASE RATING SCALE; UNIFIED PARKINSON DISEASE RATING SCALE NONMOTOR EXPERIENCES OF DAILY LIVING; WAKEFULNESS; COMPLICATION; DISEASE COURSE; DRUG COMBINATION; FEMALE; MALE; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; APATHY; DEPRESSION; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FATIGUE; FEMALE; HUMANS; INDANS; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; SLEEP; TREATMENT OUTCOME; WAKEFULNESS;

EID: 84921057086     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2014.2472     Document Type: Article

References (40)

1. Reijnders JS, Ehrt U,Weber WE, Aarsland D, Leentjens AF. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord. 2008;23(2):183-189
2. Santangelo G, Vitale C, Trojano L, et al. Relationship between depression and cognitive dysfunctions in Parkinson's disease without dementia. J Neurol. 2009;256(4):632-638.
3. Starkstein SE, Rabins PV, BerthierML, Cohen BJ, Folstein MF, Robinson RG. Dementia of depression among patients with neurological disorders and functional depression. J Neuropsychiatry Clin Neurosci. 1989;1(3):263-268.
4. Starkstein SE, Preziosi TJ, Bolduc PL, Robinson RG. Depression in Parkinson's disease. J Nerv Ment Dis. 1990;178(1):27-31.
5. Weintraub D, Moberg PJ, Duda JE, Katz IR, Stern MB. Recognition and treatment of depression in Parkinson's disease. J Geriatr Psychiatry Neurol. 2003;16(3):178-183.
6. Richard IH, McDermottMP, Kurlan R, et al; SAD-PD Study Group. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology. 2012;78(16):1229-1236.
7. Rocha FL, Murad MG, Stumpf BP, Hara C, Fuzikawa C. Antidepressants for depression in Parkinson's disease: systematic review and meta-analysis. J Psychopharmacol. 2013;27(5):417-423.
8. Mann JJ, Aarons SF,Wilner PJ, et al. A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl: a selective monoamine oxidase inhibitor. Arch Gen Psychiatry. 1989;46(1):45-50.
9. Sunderland T, Cohen RM, Molchan S, et al. High-dose selegiline in treatment-resistant older depressive patients. Arch Gen Psychiatry. 1994;51(8):607-615.
10. Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 2009;8(5):464-474.
11. Kehagia AA, Barker RA, Robbins TW. Cognitive impairment in Parkinson's disease: the dual syndrome hypothesis. Neurodegener Dis. 2013;11(2):79-92.
12. Thobois S, Lhommée E, Klinger H, et al. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. Brain. 2013;136(pt 5):1568-1577.
13. Connolly KR, Thase ME. If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs. 2011;71(1):43-64.
14. Olanow CW, Rascol O, Hauser R, et al; ADAGIO Study Investigators. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med. 2009;361(13):1268-1278.
15. Fahn S, Elton RL; Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, et al, eds. Recent Developments in Parkinson's Disease. Florham Park, NJ: Macmillan Health Care Information; 1987:153-163.
16. Goetz CG, Tilley BC, Shaftman SR, et al; Movement Disorder Society UPDRS Revision Task Force. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129-2170.
17. Brown RG, Dittner A, Findley L,Wessely SC. The Parkinson fatigue scale. Parkinsonism Relat Disord. 2005;11(1):49-55.
18. Cohen J. Statistical Power Analysis for the Behavioral Sciences. New York, NY: Academic Press;1977.
19. Thébault JJ, Guillaume M, Levy R. Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor. Pharmacotherapy. 2004;24(10):1295-1305.
20. Picillo M, Rocco M, Barone P. Dopamine receptor agonists and depression in Parkinson's disease. Parkinsonism Relat Disord. 2009;15(suppl 4):S81-S84.
21. Robinson DS, Gilmor ML, Yang Y, et al. Treatment effects of selegiline transdermal system on symptoms of major depressive disorder: ameta-analysis of short-term, placebo-controlled, efficacy trials. Psychopharmacol Bull. 2007;40(3):15-28.
22. Corrigan MH, Denahan AQ,Wright CE, Ragual RJ, Evans DL. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety. 2000;11(2):58-65.
23. Cusin C, Iovieno N, Iosifescu DV, et al. A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder. J Clin Psychiatry. 2013;74(7):e636-e641.
24. Maricle RA, Nutt JG, Carter JH. Mood and anxiety fluctuation in Parkinson's disease associated with levodopa infusion: preliminary findings. Mov Disord. 1995;10(3):329-332.
25. Maricle RA, Nutt JG, Valentine RJ, Carter JH. Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson's disease: a double-blind, placebo-controlled study. Neurology. 1995;45(9):1757-1760.
26. Barone P, PoeweW, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(6):573-580.
27. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1993;328(3):176-183.
28. Korchounov A,Winter Y, RössyW. Combined beneficial effect of rasagiline on motor function and depression in de novo PD. Clin Neuropharmacol. 2012;35(3):121-124.
29. Aarsland D, Brønnick K, Alves G, et al. The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson's disease. J Neurol Neurosurg Psychiatry. 2009;80(8):928-930.
30. Kehagia AA, Barker RA, Robbins TW. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol. 2010;9(12):1200-1213.
31. Hanagasi HA, Gurvit H, Unsalan P, et al. The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study. Mov Disord. 2011;26(10):1851-1858.
32. Jokinen P, Brück A, Aalto S, Forsback S, Parkkola R, Rinne JO. Impaired cognitive performance in Parkinson's disease is related to caudate dopaminergic hypofunction and hippocampal atrophy. Parkinsonism Relat Disord. 2009;15(2):88-93.
33. Sawamoto N, Piccini P, Hotton G, Pavese N, Thielemans K, Brooks DJ. Cognitive deficits and striato-frontal dopamine release in Parkinson's disease. Brain. 2008;131(pt 5):1294-1302.
34. Arnaldi D, Campus C, FerraraM, et al. What predicts cognitive decline in de novo Parkinson's disease? Neurobiol Aging. 2012;33(6):1127e11-e20.
35. Happe S, Baier PC, Helmschmied K, Meller J, Tatsch K, PaulusW. Association of daytime sleepiness with nigrostriatal dopaminergic degeneration in early Parkinson's disease. J Neurol. 2007;254(8):1037-1043.
36. Richard IH, Kurlan R, Tanner C, et al; Parkinson Study Group. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Neurology. 1997;48(4):1070-1077.
37. Rascol O, Fitzer-Attas CJ, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol. 2011;10(5):415-423.
38. Lang AE, Eberly S, Goetz CG, et al; LABS-PD Investigators. Movement disorder society unified Parkinson disease rating scale experiences in daily living: longitudinal changes and correlation with other assessments. Mov Disord. 2013;28(14):1980-1986.
39. Valera E, Ubhi K, ManteM, Rockenstein E, Masliah E. Antidepressants reduce neuroinflammatory responses and astroglial alpha-synuclein accumulation in a transgenic mouse model of multiple system atrophy. Glia.2014;62(2):317-337.
40. Schapira AH. Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects. CNS Drugs. 2011;25(12):1061-1071.